Sotrovimab: a new therapeutic option in lung transplant

Introduction: SARS-CoV2 infecction has a high impact on lung transplant patients. Sotrovimab, an Ig1 monoclonal antibody, has been shown to be effective for the treatment of SARS-CoV2 infection, and could be an option for these patients. Aims and objectives: Describe the evolution of the patients who have received treatment with Sotrovimab. Method(s): Observational retrospective study, which included lung transplant patients who received Sotrovimab for SARS-CoV2 infection, at the Puerta de Hierro Hospital. The study period is from November 2021 to January 2022. Variables: age, sex, type of transplant, days from Active Infection Diagnostic Test (AIDT) until drug administration, admission unit - ward, Intermediate Respiratory Care Unit (IRCU) or Intensive Care Unit (ICU) and days of admission. Also need for respiratory support, complications and death. Result(s): A total of 13 patients (9 males) with a mean age of 61 years (+/-12.3) with doble-lung transplant in 10 of them. The mean time from the AIDT until recieve Sotrovimab was 6+/-3 days. All patients required hospitalization with a mean of stay 16+/-11 days. 5 patients were admitted to the IRCU and 1 patient to the ICU. 2 patients were still hospitalized at the time of data collection (1 in the IRCU and 1 in the ICU). All patients required respiratory support (table 1). The complications are described in table 1. 3 patients died. Conclusion(s): Sotrovimab is a therapeutic option in lung transplant patients with SARS-CoV2 infection.

SEPAR Recommendations for COVID-19 Vaccination in Patients With Respiratory Diseases

The Spanish Society of Pneumonology and Thoracic Surgery (SEPAR) has elaborated this document of recommendations for COVID-19 vaccination in patients with respiratory diseases aimed to help healthcare personnel make decisions about how to act in case of COVID-19 vaccination in these patients. The recommendations have been developed by a group of experts in this field after reviewing the materials published up to March 7, 2021, the information provided by different scientific societies, drug agencies and the strategies of the governmental bodies up to this date. We can conclude that COVID-19 vaccines are not only safe and effective, but also prior in vulnerable patients with chronic respiratory diseases. In addition, an active involvement of healthcare professionals, who manage these diseases, in the vaccination strategy is the key to achieve good adherence and high vaccination coverage.